Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C

Journal of Hepatology

Volumn 28, Issue 3, 1998, Pages 382-389

  Shiffman, Mitchell L ^a   Hofmann, Charlotte M ^a   Luketic, Velimir A ^a   Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GM CSF; Hepatitis C; Interferon alpha

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MIXTURE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIREMIA;

EID: 0032030742     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80310-3     Document Type: Article

References (31)

1. Arai K, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines: coordinators of immune and inflammatory responses. Ann Rev Biochem. 59:1990;783-836.
2. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter, randomized, controlled trial. N Engl J Med. 321:1989;1501-1506.
3. DiBisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med. 321:1989;1506-1510.
4. Larrick JW, Wright SC. Cytokine modulation of viral infections. Kunkel SL, Remick DG. Cytokines in Health and Disease. 1992;181-195 Marcel Dekker, New York.
5. Issacs A, Lindenmann J. Virus interference. I. The interferon. J Immunol. 147:1957;258-270.
6. Pestka S, Langer JA, Zoon KC, Samuel C. Interferons and their action. Ann Rev Biochem. 56:1987;727-777.
7. Peters M. Mechanisms of action of interferons. Semin Liver Dis. 9:1989;235-239.
8. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 13:1991;393-397.
9. Chemello I, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. Hepatology. 22:1995;700-706.
10. Wong GG, Witek JS, Temple PA, Wilkens KM, Leary AC, Luxenberg DP, et al. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science. 228:1985;810-815.
11. Sieff CA, Niemeyer CM, Mentzer SJ, Faller DV. Interleukin-1, tumor necrosis factor and the production of colony-stimulating factors by cultured mesenchymal cells. Blood. 72:1988;1316-1323.
12. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors. N Engl J Med. 321:1989;1449-1459.
13. Metcalf D, Begley LG, Johnson GR, Nicola NA, Vadas MA, Lopez AF, et al. Biologic properties in vitro of a recombinant human GM-CSF. Blood. 67:1986;37-45.
14. Weisbart RH, Golde DW, Clark SC, Wong GG, Gasson JC. Human GM-CSF is a neutrophil activator. Nature. 314:1985;361-363.
15. Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Cytokines in chronic inflammatory arthritis. IV. GM-CSF-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med. 170:1989;865-875.
16. Gabrilove JL. Introduction and overview of hematopoietic growth factors. Semin Hematol. 26:1989;1-4.
17. Morrissey PJ, Bressler L, Parks LS, Alpert A, Gillis S. GM-CSF augments the primary antibody response by enhancing the functions of antigen-presenting cells. J Immunol. 139:1987;1113-1119.
18. Van Thiel DH, Faruki H, Fagiuoli S, Friedlander L, Wright HI, Caraceni P, et al. Successful treatment of end-stage liver disease due to hepatitis C prior to liver transplantation [abstract]. Hepatology. 20:1994;137.
19. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
20. Ferrell L, Wright T, Roberts J, Ascher N, Lake J. Hepatitis C viral infection in liver transplant recipients. Hepatology. 16:1992;865-876.
21. Gretch DR, Bacchi CE, Corey L, Dela Rosa C, Lesniewski RR, Kowdley K, et al. Persistent hepatitis C virus infection after live transplantation: clinical and virologic features. Hepatology. 22:1995;1-9.
22. Martin J, Navas S, Quiroga JA, Carreno V. Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients. Cytokine. 8:1996;313-317.
23. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 332:1995;1457-1462.
24. Shiffman ML, Hofmann CH, Luketic VA, Sanyal AJ, Contos MA, Mills AS. Gradual reduction in interferon dose reduces the incidence of relapse in patients with chronic hepatitis C: results of a randomized controlled trial. Hepatology. 24:1996;21-26.
25. Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest. 99:1997;3025-3033.
26. Gately MK. Interleukin-12: potential clinical applications in the treatment of chronic viral hepatitis. J Viral Hepat. 4:1997;33-39. (Suppl 1).
27. Cavanaugh VJ, Guidotti LG, Chisari FV. Interluekin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol. 71:1997;3236-3243.
28. Guida S, Fiore M, Scotese I, Iorio R, Gaetaniello L, Vegnente A, et al. Defective interleukin-2 production in children with chronic hepatitis B: role of adherent cells. J Pediatr Gastroenterol Nutr. 24:1997;312-316.
29. Reiser M, Marousis CG, Nelson DR, Lauer G, González-Peralta RP, Davis GL, et al. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. J Hepatol. 26:1997;471-478.
30. Malaguarnera M, Di Fazio I, Romeo MA, Restuccia S, Laurino A, Trovato BA. Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus. J Gastroenterol. 32:1997;211-215.
31. Kuzushita N, Hayashi N, Katayama K, Kanto T, Oshita M, Hagiwara H, et al. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol. 32:1997;169-174.